Concord Biotech (CONCORDBIO) Share Price Falls 5.19% to Rs 1,478.25

Published:   24 September 2026 at 1:49:12 PM IST

Concord Biotech Share Price came under pressure today, with the stock closing at Rs 1,478.25, down 5.19% from the previous close of Rs 1,559.20. The company’s market capitalisation stands at Rs 16,013.08 crore, placing it in the Mid Cap category. This Concord Biotech Share Price move is relevant because the decline happened in a listed company with a relatively rich valuation profile and a sizeable healthcare market presence. As with other Concord Biotech Stock News updates tracked by Univest, the key question is not only what changed in the price, but also how the move compares with its financial ratios, sector benchmark and peer set.

Today’s decline is a factual share price fall rather than a company-specific event explanation. The supplied data confirms the price event, but it does not establish a company-specific catalyst. That makes a structured Concord Biotech Share Price Today review useful for readers searching Concord Biotech News Today, Concord Biotech Share News and Concord Biotech Share Price Live.

Concord Biotech (CONCORDBIO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,478.25
Previous Close	Rs 1,559.2
Today's Move	-Rs 80.95 (-5.19%)
Open	Rs 1,550.15
High	Rs 1,550.85
Low	Rs 1,473.9
Turnover	Rs 2.93 crore
Market Capitalisation	Rs 16,013.08 crore
Market Cap Category	Mid Cap

Concord Biotech Share Price Today opened at Rs 1,550.15, touched an intraday high of Rs 1,550.85 and a low of Rs 1,473.90 before closing at Rs 1,478.25. The stock moved Rs 80.95 lower on the day, which translates into a 5.19% decline versus the previous close of Rs 1,559.20. That places today’s move in the context of a clear single-session price fall, with the close finishing much nearer to the day’s low than the day’s high.

The turnover for the session was Rs 2.93 crore. On the market-cap side, Concord Biotech is in the Mid Cap category and carries a market capitalisation of Rs 16,013.08 crore. For readers tracking Concord Biotech Share Price Update and Concord Biotech Stock Performance, the important verified facts are the gap between the opening price and closing price, the 5.19% decline, and the session range from Rs 1,473.90 to Rs 1,550.85. Univest presents this as a price-action event first, without attaching an unverified trigger.

For anyone searching why Concord Biotech Share Price Today moved lower, the supplied data supports the decline itself but not a specific company news catalyst. That makes the next layer of analysis the balance sheet, valuation and industry context around Concord Biotech Share Price.

Concord Biotech (CONCORDBIO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 16,013.08 crore
P/E Ratio	59.23x
P/B Ratio	7.87x
ROE	13.54%
ROCE	18.04%
EPS	Rs 26.32
Book Value Per Share	Rs 198.2
Dividend Yield	0.48%

Concord Biotech Share Price is trading against a set of fundamentals that place the company on the premium side of the healthcare universe. The stock’s P/E ratio is 59.23 and its P/B ratio is 7.87. Its ROE is 13.54% and ROCE is 18.04%, while EPS stands at Rs 26.32 and book value is Rs 198.20 per share. The dividend yield is 0.48%, which is a factual yield metric rather than a payout forecast.

These numbers matter because they show how Concord Biotech Share Price is being valued relative to earnings and accounting value. The market capitalisation of Rs 16,013.08 crore and the Mid Cap classification provide company-size context, while the enterprise-value style comparison is better understood through sector and peer valuation rather than isolated ratio reading. Univest uses these figures to frame Concord Biotech Stock Analysis in a way that separates price movement from business fundamentals. The data set does not include a company description or financial mix beyond these ratios, so the most responsible reading is that valuation remains an important lens on Concord Biotech Share Price Today.

For readers coming in through Concord Biotech Latest News or Concord Biotech Company News, the main fundamental takeaway is simple: the stock fell today even as the supplied profitability and valuation metrics remained unchanged in the dataset.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	59.23x
Benchmark Median P/E	31.9x
Benchmark Average P/E	50.01x
Benchmark P/E Range	3.48x to 762.66x
Company P/B Ratio	7.87x
Benchmark Median P/B	3x
Benchmark Average P/B	4.38x
Company ROE	13.54%
Benchmark Median ROE	11.7%
Benchmark Average ROE	10.65%
Company ROCE	18.04%
Benchmark Median ROCE	13.46%
Benchmark Average ROCE	13.26%
Company Market Capitalisation	Rs 16,013.08 crore
Benchmark Median Market Cap	Rs 761.61 crore
Benchmark Average Market Cap	Rs 14,299.75 crore

The stock belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. In the same industry benchmark set, which covers 200 companies, Concord Biotech Share Price has a P/E of 59.23 against a median of 31.9 and an average of 50.01. That places the company above both the benchmark median and benchmark average. Its P/B of 7.87 is above the industry median of 3 and above the average of 4.38.

On profitability, Concord Biotech’s ROE of 13.54% is above the benchmark median of 11.7% and above the average of 10.65%. Its ROCE of 18.04% is also above the benchmark median of 13.46% and above the average of 13.26%. The sector snapshot also shows market-cap context across 200 companies, with a median of Rs 761.61 crore and an average of Rs 14,299.75 crore. Concord Biotech’s market capitalisation of Rs 16,013.08 crore sits above the benchmark average and far above the benchmark median. For Concord Biotech Share Price News readers, the sector picture indicates a company that is valued at a premium to broad industry norms on P/E and P/B, while also showing profitability ratios above the benchmark central tendency.

Sector context does not explain today’s fall, but it does help position Concord Biotech Share Price within the pharmaceuticals set that investors commonly use for Concord Biotech Fundamental Analysis and relative valuation checks.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,42,437.37	37	5.17	14.85	19.11
Divi's Laboratories	DIVISLAB	2,48,053.84	87.1	14.42	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,841.6	86.85	21.1	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,810.19	25.85	4.33	19.69	21.39
Cipla	CIPLA	1,11,565.25	33.08	3.17	11.83	16

Among the supplied listed peers, Concord Biotech Share Price can be viewed alongside large healthcare names such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla On valuation, Concord Biotech’s P/E of 59.23 is above Sun Pharma’s 37 and Cipla’s 33.08, but below Divi’s Laboratories at 87.1 and Torrent Pharmaceuticals at 86.85. It is also above Zydus Lifesciences at 25.85.

On profitability, Concord Biotech’s ROE of 13.54% is below Zydus Lifesciences at 19.69%, Divi’s Laboratories at 16.19% and Torrent Pharmaceuticals at 26.76%, but above Cipla at 11.83%. Its ROCE of 18.04% is below Divi’s Laboratories at 21.51% and Zydus Lifesciences at 21.39%, while remaining above Cipla at 16%. In market-cap terms, Concord Biotech’s Rs 16,013.08 crore stands below Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. This is the kind of relative set that Univest uses for a practical Concord Biotech Share Price comparison, not as a forecast but as a factual reference point for Concord Biotech Stock Analysis.

Why Investors Are Watching Concord Biotech

• Concord Biotech Share Price fell 5.19% today to Rs 1,478.25, below the previous close of Rs 1,559.20.
• The session range was Rs 1,473.90 to Rs 1,550.85, with the stock closing closer to the day’s low.
• The company’s market capitalisation is Rs 16,013.08 crore, and it is classified as Mid Cap.
• The stock’s P/E is 59.23 and P/B is 7.87, with ROE of 13.54% and ROCE of 18.04%.
• In the same industry benchmark, Concord Biotech’s P/E, P/B, ROE and ROCE can be compared with 200 companies.

About Concord Biotech

Concord Biotech operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied dataset does not include a longer business description, product mix or segment breakdown, so the company overview here remains to the verified classification and market data. Even within that narrow frame, Concord Biotech Share Price can be studied through its market capitalisation, valuation multiples and profitability ratios. For readers using Concord Biotech Stock News as a starting point, the sector and industry labels remain the most dependable company-profile anchors in this dataset.

Track Concord Biotech Share Price on Univest

Use Concord Biotech (CONCORDBIO) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

On Univest, readers can track Concord Biotech Share Price Live, Concord Biotech Share Price Today, valuation ratios, shareholding pattern, 52-week levels and broader market insights in one place. Univest also helps users follow Concord Biotech Stock News, Concord Biotech Share Price Fall updates and Concord Biotech Stock Performance with structured data.

Frequently Asked Questions

Why did Concord Biotech Share Price fall today?

Ans.  Concord Biotech Share Price fell 5.19% to Rs 1,478.25. The supplied data confirms the decline, but it does not establish a company-specific catalyst or event behind the move. The previous close was Rs 1,559.2.

What was the previous close for Concord Biotech Share Price Today?

Ans.  The previous close was Rs 1,559.20. Today’s close at Rs 1,478.25 means the stock declined Rs 80.95 in the session, which is the factual basis for the price fall. The stock moved 5.19% lower during the session.

What is Concord Biotech’s market capitalisation?

Ans.  Concord Biotech’s market capitalisation is Rs 16,013.08 crore. The stock is classified as Mid Cap in the supplied dataset, which is company-size context rather than an explanation for the day’s move.

How is Concord Biotech valued on a P/E basis?

Ans.  Concord Biotech’s P/E ratio is 59.23. That is above the industry median of 31.9 and above the industry average of 50.01 in the same Pharmaceuticals & Drugs benchmark set. The company trades at a P/E ratio of 59.23x.

What do ROE and ROCE show for Concord Biotech Share Price?

Ans.  Concord Biotech’s ROE is 13.54% and ROCE is 18.04%. Both are above the industry medians in the supplied benchmark, which gives context for Concord Biotech Share Price and valuation reading.

How does Concord Biotech compare with peers?

Ans.  Concord Biotech’s P/E of 59.23 is below Divi’s Laboratories and Torrent Pharmaceuticals, but above Sun Pharma, Cipla and Zydus Lifesciences. Its market cap is also below those larger peers. Comparable listed companies include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals.